Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes
Andrew F. Ziolkowski, … , Christopher R. Parish, Charmaine J. Simeonovic
Andrew F. Ziolkowski, … , Christopher R. Parish, Charmaine J. Simeonovic
Published December 19, 2011
Citation Information: J Clin Invest. 2012;122(1):132-141. https://doi.org/10.1172/JCI46177.
View: Text | PDF
Research Article Metabolism

Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes

  • Text
  • PDF
Abstract

The autoimmune type 1 diabetes (T1D) that arises spontaneously in NOD mice is considered to be a model of T1D in humans. It is characterized by the invasion of pancreatic islets by mononuclear cells (MNCs), which ultimately leads to destruction of insulin-producing β cells. Although T cell dependent, the molecular mechanisms triggering β cell death have not been fully elucidated. Here, we report that a glycosaminoglycan, heparan sulfate (HS), is expressed at extraordinarily high levels within mouse islets and is essential for β cell survival. In vitro, β cells rapidly lost their HS and died. β Cell death was prevented by HS replacement, a treatment that also rendered the β cells resistant to damage from ROS. In vivo, autoimmune destruction of islets in NOD mice was associated with production of catalytically active heparanase, an HS-degrading enzyme, by islet-infiltrating MNCs and loss of islet HS. Furthermore, in vivo treatment with the heparanase inhibitor PI-88 preserved intraislet HS and protected NOD mice from T1D. Our results identified HS as a critical molecular requirement for islet β cell survival and HS degradation as a mechanism for β cell destruction. Our findings suggest that preservation of islet HS could be a therapeutic strategy for preventing T1D.

Authors

Andrew F. Ziolkowski, Sarah K. Popp, Craig Freeman, Christopher R. Parish, Charmaine J. Simeonovic

×

Figure 3

Enzymatically active heparanase is expressed by DI MNCs in NOD mice.

Options: View larger image (or click on image) Download as PowerPoint
Enzymatically active heparanase is expressed by DI MNCs in NOD mice.
(A)...
(A) H&E and Alcian blue staining of NOD/Lt islets demonstrated that intact islets without insulitis (I) or islets with NDI contained extensive HS. In contrast, DI (arrow) was associated with local disruption of islet HS (asterisks). Scale bars: 100 μm. (B) Quantification of islet area stained by Alcian blue showed a significant reduction in islet-associated HS in prediabetic (PD) and onset-diabetic (OD) NOD/Lt mice compared with NOD/SCID (Sc) mice. Y, young 4- to 5-week-old NOD/Lt donors. n = 60–70 islets/group, 6–7 pancreases/group. Data are mean ± SEM. *P < 0.001. (C) Stereomacroscopic view of prediabetic NOD/Lt islets showing a clear, well-defined boundary of an intact islet and islets with insulitis, indicated by a translucent appendage of insulitis MNCs (arrows). (D) Hpse and (E) Cd45 transcript expression in isolated islets, expressed relative to CBA/H kidney (K) and NOD/SCID islets, respectively. N, normal CBA/H donors. Results are mean ± SD (n = 3 per group). *P < 0.0001. (F) Heparanase immunohistochemistry showed strong expression of heparanase protein by DI MNCs in a diabetes-onset NOD/Lt pancreas (HP130 mAb). Note weak cell surface expression of heparanase (arrows) on NOD/SCID and diabetes-onset NOD/Lt islet cells. Scale bars: 100 μm. (G) Western blot analysis of mouse proheparanase (prohpse; 1453 pAb; 65 kDa) and active heparanase (hpse; HP130 mAb; 48 kDa) in protein extracts from pooled islets (10 donors/group). Heparanase (50 ng) purified from human platelets (Hu Hpse) was included as a 50-kDa standard.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts